AbbVie’s new AI deal; Roche’s PhIII win in breast cancer; SpringWorks to raise $275M

Plus, news about Eli­go Bio­science, Eye­Point, Xenon and Merus:

Ab­b­Vie signs AI pact: For $30 mil­lion up­front, the phar­ma is part­ner­ing with BigHat Bio­sciences to de­vel­op new an­ti­bod­ies in on­col­o­gy and neu­ro­science. It’s the sec­ond bio­phar­ma AI al­liance to be an­nounced on Tues­day. Ab­b­Vie could dish out up to $325 mil­lion more in R&D mile­stones. — Kyle LaHu­cik

Roche touts PhI­II breast can­cer win for PI3K al­pha drug: The Big Phar­ma’s in­avolis­ib plus Pfiz­er’s Ibrance achieved a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in the pri­ma­ry end­point of pro­gres­sion-free sur­vival in peo­ple with PIK3CA-mu­tat­ed HR-pos­i­tive HER2-neg­a­tive ad­vanced or metasta­t­ic dis­ease. Roche plans to present the full da­ta at a fu­ture meet­ing and then sub­mit them to health au­thor­i­ties. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.